Various Bortezomib Policies It Is Important To Keep In Mind

The mean percentage of time within the therapeutic range for warfarin (INR 2.0�C3.0) was 64%. Stroke or systemic embolism occurred at a rate of 1.69% per year in patients receiving warfarin and 1.53% and 1.11% per year, respectively, in those treated with 110 or 150?mg dabigatran. Both doses of dabigatran were noninferior to warfarin (P? http://www.selleckchem.com/products/PD-0332991.html P?=?0.048). However, after a subsequent revision of the database, new events were detected, adjudicated in a blinded fashion and in accordance with the study protocol, and the significant difference regarding the rates of myocardial infarction was no longer evident [16]. After a further recent revision of the RE-LY results, it was found that there was a nonsignificant increase http://www.selleck.cn/products/Bortezomib.html in myocardial infarction with dabigatran compared with warfarin and that other clinical events related to myocardial ischaemia were not increased [17]. However, it should be noted that treatment with dabigatran was found to be associated with a significantly increased odds ratio (1.33; 95% CI 1.03�C1.71) for myocardial infarction or acute coronary syndrome in a recent meta-analysis of seven randomized trials [18]. With regard to safety, the rate of major bleeding was 3.36% per year in the warfarin group, 2.71% per year in the 110?mg dabigatran group (RR 0.80; 95% CI, 0.69�C0.93; P?=?0.003) and 3.11% per year in the 150?mg dabigatran group (RR 0.93; 95% CI, 0.81�C1.07; P?=?0.31). Of particular interest are the lower rates of intracranial bleeding recorded in patients who received dabigatran: 0.74% per year in the warfarin group and 0.23% and 0.30% per year in the 110?mg and 150?mg dabigatran groups, with an RR of 0.31 and 0.40 (both P?11% with either dose) and significantly http://www.selleckchem.com/products/Everolimus(RAD001).html more frequent than in the warfarin group (P?